Merck is discontinuing its insulin biosimilar Lusduna, the company announced Thursday (Oct. 11), but, unlike most biologics, insulin is covered by Medicare Part D instead of Part B where biosimilar makers can make a bigger profit, so the Lusduna discontinuation is not seen as a bellwether of biosimilar market erosion, brand drug and analyst sources said. However, Momenta’s announcement Oct. 1 that it is dropping most of its biosimilars program is likely an indication that smaller drug makers will have...